c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms.
To evaluate the role of the Ki-67 proliferation antigen and c-erbB-2/neu oncogene expression in the clinical assessment of salivary gland tumors, we followed up 71 patients with minor salivary tumors of the palate. All benign neoplasms (n = 18) showed low Ki-67 scores (< 12%), whereas 26% (14 of 53) of malignant neoplasms manifested high Ki-67 scores (> 12%). A significant statistical difference between Ki-67 scores for benign and malignant neoplasms was observed (p < 0.001). Ki-67 index also correlated significantly with malignant tumor grade (p = 0.04) and patient survival (p = 0.02). Only 1 of the 18 benign tumors had c-erbB-2/neu oncogene overexpression. A significant difference between c-erbB-2/neu overexpression in benign and malignant tumors was observed (p = 0.01). Overexpression of c-erbB-2/neu oncogene was noted in 38% (16 of 42) of malignant tumors and was significantly associated with aggressive tumor behavior (p < 0.001). Multivariate analysis of significant factors revealed that gender, tumor stage, and c-erbB-2/neu oncogene overexpression were jointly predictive of survival. Our data indicate that although the Ki-67 proliferating antigen and c-erbB-2/neu oncogene expression may reflect certain intrinsic biologic properties of these neoplasms, only c-erbB-2/neu overexpression is significantly associated with their biologic aggression.
Giannoni
C
C
Department of Otolaryngology, Baylor College of Medicine, Houston, TX.
el-Naggar
A K
AK
Ordoñez
N G
NG
Tu
Z N
ZN
Austin
J
J
Luna
M A
MA
Batsakis
J G
JG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003528:Carcinoma, Adenoid Cystic / Q000235:genetics / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D019394:Ki-67 Antigen; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics; D009687:Nuclear Proteins / Q000032:analysis* / Q000235:genetics; D010157:Palatal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D012468:Salivary Gland Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D012470:Salivary Glands, Minor / Q000378:metabolism*; D015996:Survival Rate; D016896:Treatment Outcome
D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins